top-banner

NEWS ROOM

Medicover Genetics publishes insights on advances in non-invasive prenatal testing

Medicover Genetics is pleased to announce the publication of an article by PD Markus Stumm in Scientia highlighting advances in screening for genetic abnormalities with non-invasive prenatal testing (NIPT).

In the article, Dr. Stumm explains how NIPT uses fetal cell-free DNA (cfDNA) extracted from a maternal blood sample to screen for potential chromosomal abnormalities, including trisomy 13 (Patau syndrome), 18 (Edwards syndrome), and 21 (Down syndrome).

A key focus of the article is the use of Target Capture Sequences (TACS), long synthetic DNA probes designed by Medicover Genetics Cyprus, to analyze the cfDNA. TACS target specific genome regions of interest and avoid unnecessary regions, improving the precision and accuracy of the test. The article continues with a valuable discussion for clinicians about the importance of fetal fraction—the proportion of cfDNA in the maternal bloodstream—for ensuring accurate results in NIPT.

Dr. Stumm concludes the article by noting, “With further technological advances and responsible innovation, NIPT remain a screening avenue for the detection of additional genetic conditions.”

Read the full article here.

OUR NETWORK